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Diabetes is a life-long chronic condition that is an established risk factor for the development of comorbid depression and possibly affecting 
medication adherence. Psychological and educational interventions are reported efficacious by the National Institute for Health and Care 
Excellence (NICE) in treating depression associated with a comorbid condition. As depression is associated with low adherence rates to 
treatment regimens, improving depression outcomes could improve adherence and therefore glycaemic control. A search strategy was 
conducted on search engines Google Scholar, PubMed, and Cochrane library for clinical trials. A total of 10 Randomised controlled trials 
(RCTs) were identified which investigated the effects of psychological and educational interventions on Type 2 diabetic patients with 
comorbid depression. Outcomes measured were depression and glycaemic control. Evidence from the 10 RCTs with 5759 participants 
suggests that psychological and educational intervention improved depression outcomes substantially and glycaemic control to an extent. 
Depression outcomes results were significant: standard mean deviation (SMD) was -0.39 (95% CI -0.62, -0.15); I2= 81%) p<0.001. Diabetes 
outcomes were not seen to be significant, SMD was -0.14 (95% CI -0.32, 0.03); I2= 44%) p=0.12. Psychological and educational interventions 
are effective in improving depression symptoms significantly and may assist in glycaemic control. Further research is required using larger 
sample sizes that could be generalized and representative of the whole population.  
 




Diabetes is a common condition with a prevalence of 4.7 
million in the UK, with type 2 diabetes accounting for 90% 
of that [1]. Type 2 diabetes arises due to the body 
ineffectively using the insulin produced otherwise known as 
insulin resistance and/or an inability to produce sufficient 
insulin [2, 3]. It is characterized by the inability to metabolize 
glucose which leads to high blood sugar.  
Managing diabetes is a lifelong process requiring devotion 
from patients as most of the treatment centers on self-
management, patients and their families are the key to 
maintaining their disease control. Poor management leads to 
serious diabetes complications in the future such as diabetic 
retinopathy and diabetic foot disease [4]. 
Depression is defined as persistent low mood combined with 
a loss of pleasure in most activities including a variety of 
emotional, cognitive, and behavioral symptoms. It has a 
prevalence of 4.5% in the UK and it is the leading cause of 
disability and premature death [5]. Other possible causes such 
as genetic vulnerability, life events, medication, and medical 
problems [5]. 
Pharmacists’ role in the management of diabetes 
and depression  
 Pharmacies play a major role in the management of diabetes 
and depression as they increasingly offer many services 
including screening, foot health checks and influenza 
vaccination for diabetes, and general well-being advice for 
depression. Early detection of both conditions may reduce 
morbidity and mortality rates. Pharmacists can play a major 
role, particularly with depression as they are often trained to 
suspect any early symptoms associated with depression [6]. 
It is expected that people with chronic illnesses are at a higher 
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Adherence and Non-adherence  
 Adherence is defined as the extent to which the patient’s 
behavior matches agreed-on recommendations from the 
prescriber. It highlights how patients have freedom of choice 
whether to adhere to their prescriber’s recommendations [8]. 
This ultimately suggests that since patients have full 
autonomy in their treatment, they are responsible and play a 
major role in adherence to treatment. Non-adherence is 
defined as resistance to adhering correctly to treatment. This 
could be in the form of missed doses, skipping routine check-
ups, or completely not taking medication [9]. Non-adherence 
can be grouped under two different types, one being 
unintentional which refers to factors such as forgetfulness or 
potential physical disabilities of which the patient may not be 
in total control. Whilst intentional non-adherence is a 
personal choice made by the patient to deliberately not take 
their medication [10]. Recent data has shown that adherence 
to long-term treatment in patients with chronic conditions is 
below 50% [11]. This could be linked to diabetes which is a 
long-term condition, and patients' neglect in adherence to 
diabetes treatment therapy. 
Psychological and Educational Intervention 
Cognitive behavior therapy is a type of treatment that focuses 
on helping people manage their problems by changing the 
way they think and behave through teaching coping skills 
[12]. Educational interventions can differ depending on what 
the healthcare professional assesses the patient requires most 
and often include methods such as counseling and one-to-one 
support in understanding their management plan from 
healthcare professionals [13]. Such interventions have been 
used, and have proven effective in improving medication 
adherence provided that specific strategies that are best suited 
to the individual are identified and put into practice [14]. 
NICE CG91 guideline (2009) states that treating depression 
in chronic conditions has the potential to increase the quality 
of life (QoL) and has recommended a stepped care model 
which provides an outline that helps healthcare professionals 
to identify the most effective interventions which include 
psychological (CBT) and educational collaborative care [15]. 
Considering diabetes is a chronic life-long condition, a link 
has been identified between diabetes and the development of 
comorbid depression. It has been shown that depression 
worsens an individual’s mental state and consequently self-
care, as depressed individuals tend to not prioritize treatment 
and can be resistant to taking medication. Depression and 
certain antidepressant medications also cause weight gain 
which can increase blood glucose levels or undereating which 
can lead to hypoglycemia which also affects diabetic control. 
This has a direct effect on the management of diabetes and 
leads to complications that cannot be as easily treated [16]. 
Interestingly, depression and diabetes share some similar 
symptoms such as lethargy and excessive sleeping. This can 
be difficult to distinguish between the two conditions which 
can lead to undiagnosed depression in some patients. A 
relationship can be made here between depression and 
uncontrolled diabetes since, as previously mentioned, 
diabetes management relies heavily on patient compliance 
[17]. This implies that efficiently managing depression in 
diabetic patients could significantly improve diabetic control.  
Limited research has examined the link between the two 
conditions. Randomized controlled trials have explored the 
impact of an intervention on the improvement of depressive 
symptoms. However, there has been little evidence to support 
that interventions improve diabetic control compared to usual 
care [18]. This analysis examines RCTs looking at 
psychological and educational interventions and the impact 
of depression on diabetes control, and whether this approach 
is feasible in practice. 
MATERIALS AND METHODS 
Overview  
This meta-analysis analyses existing RCTs and comparing 
whether there is an improvement in clinical outcomes with 
interventions such as CBT and educational programs. 
Aim  
Patients with diabetes are more prone to experience 
depression than those without diabetes. Diabetes with 
comorbid depression has been associated with poorer QoL, 
an increase in hyperglycemia, and an increase in depressive 
symptoms. This review aims to investigate how combating 
depression symptoms with the psychological intervention 
will have a positive impact on diabetes and depression 
outcomes. This was done by analyzing RCTs of diabetic 
patients with comorbid depression, where the comparison 
between treatment intervention in these patients, versus usual 
care, is studied to determine the impact on adherence. 
Objectives 
• Use RevMan 5 software to assess and analyze data from 
the RCTs. 
• Apply a critical appraisal skills programme 
(CASP)(2021) to assess the credibility of the RCT papers 
used in this analysis [19]. 
• Use search engines to find suitable RCTs for analysis. 
• Apply PRISMA (2021) to display search strategy for 
papers used in this analysis [20]. 
• Discuss and explore the link if any, between treatment 
intervention on clinical outcomes in depression and 
diabetes. 
 
Design and Protocol 
This study was a meta-analysis that combined quantitative as 
well as qualitative information from several studies and 
derives conclusions on whether interventions in depression 
and diabetes treatment have an impact on adherence and 
whether it will improve clinical outcomes.  
The PICO model was used for a focused approach to clinical 
questions on this analysis and to help in the search for papers 
that include all these factors [21]. 
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Population or problem- Diabetic patients with comorbid 
depression focusing on type 2 diabetes 
Intervention or exposure intervention is analyzing if the 
psychological and educational interventions will improve 
adherence and therefore clinical outcomes in diabetes and 
depression 
Comparison- Comparing intervention in adherence 
improvement to usual care with no intervention measures. 
Outcome- Outcomes measured were diabetes by measuring 
glycaemic control and depressive symptoms determined 
using different psychometric measures.  
Keywords  
The following keywords were used in the search strategy as 
outlined in Figure 1: Type 2 diabetes; Adherence; 
Psychological intervention; Collaborative care; Randomised 
clinical trial; Comorbid depression 
Selection criteria 
A literature search was conducted to identify RCTs on this 
topic. The search was carried out from December 2020 to 
March 2021 on databases such as Google® scholar™, 
PubMed©, and Cochrane© library. It looked at published 
RCTs from 2000-2021. The inclusion and exclusion criteria 
are detailed in the Table (1) below.
 
Table 1. Inclusion and Exclusion criteria for researched studies. 
 Inclusion criteria Exclusion criteria 
Study design 
Randomized controlled trials 
Primary studies 
Non-primary studies e.g., meta-analysis and systematic reviews 
Date Between 2000-2021 Outside 2000-2021 range 




If they did not include diabetes control and/or depression control outcomes or 
reference to adherence 
Age Over 18 years Under 18 years 
Condition T2D with comorbid depression 
Other mental illnesses 
Non-diabetic conditions 
 
Search strategy  
The search strategy found a total of 1725 papers which 
contained 1329 duplicates that were excluded. The remaining 
396 papers were briefly screened for title and PICO and were 
found to be irrelevant to this study and therefore 202 were 
excluded which left 125 papers that were screened further 
according to measured outcomes and a final quantity of 10 
studies were selected and quality assessed using CASP 
(2021). Figure 1 shows a PRISMA (2021) flow diagram of 
the series of events in the search strategy.  
 
Figure 1. PRISMA diagram showing search strategy 
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Risk of Bias  
The risk of bias analysis can help to explain variations in 
results. In this case, the risk of bias was created using 
RevMan© version 5.3 software [22]. To complete this, 
different tables were made for each study where the 
characteristics of the studies were declared using authors' 
judgments on the different areas of bias. The tables can be 
analyzed using the labels given in RevMan© of “High risk, 
low risk, and unclear risk”. Figures 2 show the resulting 
graphs following this method. 
 
Figure 2. Risk of bias summary: review authors' judgments about each risk of bias item for each included study. 
 















Intervention and usual care groups did not 
differ statistically on baseline measures. 
Patients who received the intervention 
were more likely to achieve 
HbA1c levels of less than 7% (intervention 
60.9% vs usual care 35.7%; P <.001) and 
remission of depression (PHQ-9 score of 
less than 5: intervention 58.7% vs usual 







intervention where a 
care manager 
collaborated with 
physicians to offer 
education and guide 
patients to improve 
and monitor 
adherence. 
Brief intervention integrating 
treatment of type 2 diabetes and 
depression was successful in 
improving outcomes in primary 
care. An integrated approach to 
depression and type 2 diabetes 
treatment may facilitate its 
deployment in real-world practices 
with competing demands for 
limited resources. 
Cummin
gs et al., 
RCT 139 
Using intent-to-treat analyses, patients 
in the intervention experienced marginally 
significant improvements in HbA1c (20.92 
6 1.81 vs. 20.31 6 2.04; P = 0.06) 
compared with usual care. However, 
intervention patients experienced 
significantly greater improvements in RRD 
(21.12 6 1.05 vs. 20.31 6 1.22; P = 0.001), 
depressive symptoms (23.39 65.00 vs. 
20.90 6 6.17; P = 0.01), self-care 
behaviours (1.10 6 1.30 vs. 0.58 6 1.45; 
P = 0.03), and medication adherence (1.00 
6 2.0 vs. 0.17 6 1.0; P = 0.02) versus usual 
care. Improvement in HbA1c correlated 
with improvement in RRD (r = 0.3;P = 









CBT plus lifestyle 
counselling 
Tailored CBT with lifestyle 
counselling improves behavioural 
outcomes and may 
improve HbA1c in rural patients 
with T2D and comorbid depressive 
and/or RRD 
symptoms. 










Among 6000 participants, mean (SD) age 
was 55.9 (11.0) years and 3344 (59.8%) 
were male. Compared with arm 1, insulin 
no persistence did not differ in arm 2 
(relative risk, 0.88; 95% CI, 0.75-1.03) or 
arm 3 (relative risk, 0.91; 95% CI, 0.77-
1.06). Glycaemic control was similar in 
arm 2 and arm 1 (absolute HbA1c level 
difference, –0.15%; 95% CI, –0.34% to 
0.05%) but was better in arm 3 (absolute 
HbA1c level difference, –0.25%; 95% CI, 







intervention of weekly 
text message and 
tailored pharmacist 
assistance of 12 follow 
up calls, consultations, 
and counselling 
Highly targeted high-intensity 
intervention did not improve insulin 





Baseline A1c levels were good and there 
was no difference in A1c at follow-up. 
Intervention patients experienced a4.26 
mmHg decrease in systolic blood pressure 
relative to controls (p=.05). Intervention 
patients had significantly greater increases 
in step-counts (mean difference 1,131 
steps/day; p=.0002) and greater reductions 
in depressive symptoms (58%remitted at12 
months versus 39%; p=.002). Intervention 
patients also experienced relative 









by nurses for 12 weeks 
followed by 9 monthly 
booster sessions 
This program of telephone 
delivered CBT combined with a 
pedometer-based walking program 
did not improve A1c values but 
significantly decreased patients’ 
blood pressure, increased physical 
activity, and decreased depressive 
symptoms. The intervention also 
improved patients’ functioning and 





Both groups were demographically 
homogeneous with no statistically 
significant difference. The trend in 
depression scores before as well as 2 
weeks, 4 weeks, and 2 months after the 
intervention was statistically significant in 
the experimental group (P ≤ 0.001), but not 
in the control group (P = 0.087). The 
results showed that HbA1c variation was 
statistically significant before and after the 





therapy was effective in reducing 
depression in patients with diabetes. 
Therefore, this method can be 
recommended for such patients. 
Ell et al., 
2010 
RCT 387 
INT patients had significantly greater 
depression improvement (50% reduction in 
Symptom Checklist-20 depression score 
from baseline; 57, 62, and 62% vs. the 
EUC group’s 36, 42, and 44% at 6, 12, and 
18 months. 
no intervention effect on A1C or self-care 












Sociocultural adapted collaborative 
depression care improved 
depression, functional outcomes, 
and receipt of depression treatment 
in predominantly Hispanic patients 




A total of 27 participants (66%; 27/41) 
completed the iCBT program. Analyses 
indicated between-group superiority 
of iCBT over TAU at posttreatment on 
PHQ-9 (g=0.78), PAID (g=0.80), K-10 
(g=1.06), GAD-7 (g=0.72), and SF-12 
mental well-being scores (g=0.66), but no 
significant differences in self-reported 
HbA1c levels (g=0.14), SF-12 physical 
well-being, or 
PHQ-15 scores (g=0.03-0.21). Gains were 
maintained at 3-month follow-up in the 
iCBT group, and the 87% (27/31) of iCBT 
participants who were interviewed no 
longer met criteria for MDD. Clinically 
significant change following iCBT on 
PHQ-9 scores was 51% (21/41) versus 








iCBT programme with 
a therapist support 
provided by phone and 
email 
iCBT for depression is an 
efficacious, accessible treatment 
option for people with diabetes. 
Future studies should explore 
whether tailoring of iCBT programs 
improves acceptability and 
adherence, and evaluate the long-






Linear mixed modelling found that all 
groups showed improved HbA1c levels 
(P.001). However, the structured 
behavioural arm showed greater 




Quality of life 
Self-efficacy 
CBT with educator led 
structured group 
intervention 
A structured, cognitive behavioural 
program is more effective than 2 
control interventions in improving 
glycemia in adults with long-
duration diabetes. Educators can 
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individual control arms (3- month HbA1c 
concentration changes: −0.8% vs −0.4% 
and −0.4%, respectively (P=.04 for group 
time interaction). Participants with type 2 
disease showed greater improvement than 
those with type 1.Quality of life, glucose 
monitoring, and frequency of diabetes 
selfcare did not differ by intervention over 
time. 
successfully use modified 







At baseline, mean (±SD) haemoglobin A1c 
levels were 7.28% ± 1.43%; follow-up 
values were unaffected by the intervention 
(P > 0.2). 
Intervention had less severe depression 
(range, 0 to 4 on a checklist of 20 
depression items; between-group 
difference, –0.43 [95% CI, –0.57 to –0.29]; 
P < 0.001) and greater improvement in 
overall functioning (range, 0 [none] to 10 
[unable to perform activities]; between-
group difference, –0.89 [CI, –1.46 to –










treatment, or support 
for antidepressant 
management by the 
patient’s primary care 
physician; diabetes 
care was not 
specifically enhanced. 
Collaborative care improves 
affective and functional status in 
older patients with depression and 
diabetes; however, among patients 
with good glycaemic control, such 









The experimental group showed a 
significant reduction in glycosylated 
haemoglobin, fasting glucose, and 
depressive symptoms and a significant 
increase in physical quality of life and 
mental quality of life at T2 and T3, while 
patients in the control group with usual 











Conclusion The behavioural 
intervention facilitated a significant 
improvement in psychological 
adjustment and glycaemic control, 
thus strengthening diabetes control 
skills and leading to healthy 
outcomes. It is feasible that nurses 
and psychiatrists can deliver the 
behavioural intervention for 
diabetes patients to decrease their 
depressive symptoms 
 
Selected Studies Summary  
A summary of the 10 studies included in this analysis is 
provided in Table 2. All were RCTs and in total had 5759 
participants with diabetes and comorbid depression. Out of 
the 10 studies, 6 studies explored CBT as an intervention 
whereas the remaining 4 looked at educational and 
collaborative care interventions. 
RESULTS AND DISCUSSION  
The 10 RCTs were analyzed using RevMan© by formulating 
forest plots that calculated the standard mean difference for 
depression outcomes. The data was continuous and was 
measured in different methods e.g., different psychometric 
measures: PHQ-9 score [23], BDI® (Becks depression 
inventory) score [24], and QoL© index score so that the 
results are standardized and can be compared [25]. The mean 
difference effect measure was used for diabetes outcomes as 
all data was in HbA1c (%) values. The random-effects 
analysis model was used for both measured outcomes as the 
heterogeneity was over 50%. 
Measurable outcomes 
Measured outcomes were; depression control measured with 
PHQ-9©, QoL© scores, and BDI® scores. Additionally, 
Diabetes was measured with HbA1c (%) values.  
Diabetes clinical outcome 
All 10 studies investigated diabetic control measured through 
HbA1c (%) values which are displayed in Figure 3. Only 6 
of these studies [26-31] explored T2DM, with the remaining 
4 exploring both T1DM and T2DM [32-36]. For this reason, 
a sub-group analysis was conducted and separated those two 
sets of studies to determine if that could have been a cause of 
increased heterogeneity. Only data for T2DM was used in this 
analysis.  
Overall, the combined results for HbA1c values were not 
significant (p=0.12) and a standard mean difference of -0.14 
(95% CI -0.32, 0.04). Out of the 10 trials, only 2 completely 
crossed the line of null effect which was Huang et al. [26] 
(2015) mean difference (MD) -1.33 (95% CI -2.03, - 0.63) 
and Lauffenburger et al., [27] MD -0.14 (95% CI -0.23, -0.05) 
with the latter having the highest weighting of 28.8%. The 
remaining 8 trials all had confidence intervals (CI) that 
crossed the line of null effect which shows that the study 
result no significant differences between the intervention and 
usual care groups.  
Two of the trials [29, 30] had confidence intervals evenly 
distributed between the intervention group and the usual care 
group. This was because the HbA1c value did not change 
between the two groups for all those 4 studies which show no 
significant results.  
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The averaged results, symbolized by the diamond on the 
forest plot show not significant.  
The heterogeneity of the first T2DM sub-group was I2 = 64% 
which is higher than the suggested range as it is above 50%. 
The T1DM and T2DM subgroups have heterogeneity of 0%. 
Overall, the heterogeneity was 44% with p= 0.06 which 
indicates no significant differences and that the studies are 
relatively consistent with little bias, and any differences can 
be assumed to be due to chance. 
 
 
Figure 3. Forest plot showing diabetes clinical outcomes (HbA1c values) Intervention versus usual care [24-29]. 
 
Depression clinical outcomes 
Out of the 10 studies, 9 of the trials studied depression 
outcomes in a way that was measurable using RevMan©. A 
sub-group analysis was conducted as 4 of the studies 
measured depression using PHQ-9© scores, 4 used QoL© 
scoring, and 1 used BDI®. This was done to see if any 
differences in heterogeneity were important.  
Figure 4 represents the standard mean difference in 
depression clinical outcomes between intervention and usual 
care groups. This forest plot confirms that intervention with 
CBT [37] or education improved the depression outcomes 
greatly in terms of the PHQ-9© scores sub-group (SMD -
0.63, 95% CI -1.05, -0.21) p=0.003. The forest plot was on 
the intervention side showing these studies significantly 
supported the hypothesis of intervention improving 
depression outcomes. The overall effect was SMD -0.39 
(95% Cl -0.62, -0.15) p=0.001 which is highly significant.  
In the QoL© subgroup, a high score indicated a higher 
QoL©concerning depression [25]. This is not reflected in the 
forest plots produced from RevMan© as a higher score in the 
intervention group indicates usual care favored result. For this 
reason, the results were reversed to showcase a more accurate 
representation of the results which showed 3 studies favoring 
intervention [27-29] with only one favoring the usual care 
group [30]. 
Notably, five of the trials [26, 31-34] were completely to the 
left of the null effect and showcase an unequivocal positive 
effect for the intervention. Weinger et al. [35] was the only 
trial that completely crossed the line of null effect line. 
The heterogeneity measured was relatively high for this 
outcome at 81% indicating diversity in the studies regarding 
this outcome. It is higher than 50% indicating differences 
may be due to factors other than chance. For this reason, sub-
group analysis was conducted to see if this influenced the 
heterogeneity. This showed the subgroup differences were 
43.5% (P=0.17) which was a small difference and not highly 
significant. This could be due to the different methodology 
being used in the different studies especially since the 
psychometric measurements for depression were different as 
well as differences in the patients’ baseline characteristics 
and results for depression measures. Due to the high value of 
the heterogeneity, it can be assumed that there is the bias 
associated with this outcome which can range from 
publication bias to differences in randomization in those 
trials. 
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Figure 4. Forest plot showing depression outcomes (PHQ-9© score, QoL©score, and BDI® score) intervention vs usual 
care [24, 28, 33-35]. 
 
Collaborative care, associated with the psychological 
intervention and educational programs for patients with 
diabetes and comorbid depression, has been an area that has 
not been thoroughly explored, with limited evidence on the 
effects it has on clinical outcomes and adherence. This meta-
analysis suggests that numerous interventions are required to 
maintain adherence to long-term treatment in conditions such 
as diabetes. 
Diabetes control  
Diabetic control was measured using HbAc1 levels in all 10 
RCTs to indicate if there was any change in the levels 
between baseline and following the interventions. The 
primary aim of all these studies was to determine the 
effectiveness of care interventions on adherence measured in 
outcomes of depression and diabetes control. 
A total of 6 out of 10 studies showed an improvement in 
HbA1c levels. Bogner et al. [28] found patients randomized 
to their integrated care intervention showed higher rates of 
adherence to diabetic medication. Glycaemic control was also 
improved supporting a link between adherence and 
improvement in diabetic control. Similarly, Cummings et al. 
[29] found that patients in their intervention groups 
experience an average decrease of 1.0% in HbAc1. This 
finding is consistent with a prior study conducted in the same 
year by Lauffenburger et al. [27] which also concluded that 
glycaemic control was improved with high-intensity 
interventions compared to usual care. Sharif et al. [30] and 
Weinger et al. [33] found that HbA1c mean variation was 
significant in intervention groups with Sharif et al. [30] 
stating that the change in blood glucose changes was 
significant but had uncertainty regarding intervening factors 
that could have accounted for this large change such as 
patients knowing their blood glucose levels before the 
interventions due to ethical reasons. Comparably, Huang et 
al. [26] showed that participants displayed statistically 
significant improvements in HbA1c 90 days after 
interventions which shows the potential for long-term 
improvements as well as short-term. 
Conversely, 4 out of the 10 chosen studies showed no 
improvements in diabetic control following interventions. 
Piette et al. [31] stated that although there was no 
improvement in haemoglobin A1c values, they were initially 
reasonably good at the beginning and were therefore 
unaffected by the intervention. This was identical to findings 
from Williams et al. [35] as they found that patients had good 
glycaemic control at baseline so there was limited power to 
detect small clinical changes in HbA1c levels, hence no 
improvement was observed in both studies. Newby et al. [34] 
and Ell et al. [36] also showed no differences in HbA1c levels 
with levels increasing in the intervention group compared to 
usual care. However, both of these studies measured HbA1c 
through patient self-reporting. This could be a factor in why 
there were no visible improvements. 
Depression control  
Eight out of 10 studies showed an improvement in depressive 
symptoms following the intervention. Bogner et al. [28] 
identified that compared to patients who are not depressed, 
depressed patients who have diabetes are more likely to be 
non-adherent to medication regimens, including their 
antidepressants and diabetic medications. Cummings et al. 
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[29] postulated a hypothesis that patients with T2DM are 
twice as likely to have depressive symptoms and that the 
relationship between the two could be bidirectional. Shariff 
et al. [30] and Newby et al. [34] and agreed, stating that 
proactive detection and treatment of depression is essential to 
reduce the burden of depression in people with T2DM and 
that depression interferes with metabolic control of diabetes 
leading to weak control of blood glucose levels. All of these 
studies showed improvement in depression symptoms with 
intervention. Two of the studies [26, 28] showed a decrease 
in depression scores and improvement in QoL© immediately 
after the intervention, and with Huang et al. [26] 
improvements were seen 90 days later in follow-up routine 
appointments. Newby et al. [34] and Williams et al. [35] had 
similar results whereby patients were seen to have less severe 
depression and greater progress in overall functioning than in 
usual care measures with a comparison from baseline to after 
intervention showing substantial developments. On the 
contrary, Weinger et al. [33] showed no improvements in 
depression outcomes. Since this difference has not been 
found elsewhere it can be assumed that this is possibly due to 
other factors and not solely based on intervention measures 
not being effective. 
Adherence 
Adherence is the main factor identified to have an impact on 
clinical outcomes in all chronic diseases [37]. All the studies 
evaluated whether intervention on depression had an impact 
on adherence to medication and overall improvement in 
clinical outcomes. Weinger et al. [33] identified that an 
important reason for poor glycaemic control is the patient’s 
difficulty in following treatment and self-management 
recommendations. This is directly linked to adherence, as 
adherence is the patient’s commitment to their treatment and 
if they find this difficult then it will lower disease control in 
those patients. Lauffenburger et al. [27] implied that 
effectively targeting adherence to the patients most likely to 
benefit, has the potential to improve efficacy in treatment but 
it has not been widely assessed.  
Newby et al. [34] suggested that depression could be a major 
factor in lower adherence and Ell et al. [36] looked at 
enhancing adherence by integrating depression and diabetes 
care as they projected that providing care for both diseases 
will aim to improve adherence overall for diabetes with 
comorbid depression. Bogner et al. [28] agreed as they 
explored an adherence-based approach as they stated that 
even though pharmacological treatment is highly efficacious, 
many patients do not adhere to the treatment and this is a high 
risk especially in patients with comorbid diabetes and 
depression. They hypothesized that integrating the care of the 
two with interventions would enhance adherence.  
Cummings et al. [29] suggested that depression symptoms are 
a risk factor for poor adherence, and their results showed that 
there were significant reductions in depressive symptoms and 
consequent improvement in medication adherence. Similarly, 
Huang et al. [26] found that their intervention group 
facilitated an increase in adherence rates as significant 
improvement in the psychological state helped strengthen 
diabetes by improving glycaemic control. Sharif et al. [30] 
discussed how CBT interventions were effective for treating 
depression but they have been poorly utilized in depression 
associated with physical illness. However, it has proven 
effective in diabetic patients and has been proven to improve 
adherence measured in depression outcomes which were 
evident in results observed in this study.  
Interestingly, Piette et al. [31] observed depression symptoms 
improving greatly, however, this was not reflected in the 
patient’s medication adherence as there were no important 
differences found. Medication adherence was measured using 
the Morisky© medication adherence scale. This raises the 
question of whether improvement in depression symptoms 
has an impact on medication adherence. However, this could 
be linked to the no change in glycaemic control also. 
Correspondingly, Williams et al. [35] expected effective 
treatment for depression could benefit adherence to self-care 
regimens which therefore would improve diabetic control in 
patients. They found that patients reported almost perfect 
adherence to medication however, lower adherence rates 
were reported for glucose testing and foot inspections. This 
could be explained by looking at the measure for these self-
care behaviors which showed ceiling effects, meaning that the 
participants already had high scores for the medication 
adherence so there was little room for improvement. 
Intervention  
Cognitive behavior therapy is a form of psychological 
treatment that has been proven effective for depression. It 
helps change the way of individual thinking and behavior 
[38]. Out of the 10 studies, 6 used CBT as a form of 
intervention to assess its effectiveness in improving 
adherence and consequently clinical outcomes. Cummings et 
al. [29] stated that an integrated care model involving 
delivering CBT plus lifestyle counseling to patients with T2D 
is feasible in primary care practice and has the promise to be 
highly effective. Newby et al. [34] performed a study on 
online CBT (iCBT). They stated that it is as efficacious as 
face-to-face CBT and can be delivered at a fraction of the cost 
and clinical time. CBT has been shown to help patients feel 
better when participating in enjoyable activities when they 
can discuss their mental well-being as it can help the patient 
be their therapist and use self-management skills to improve 
adherence and control depressive symptoms [29]. The rest of 
the studies looked at educational interventions as opposed to 
psychological measures. They looked at using counseling and 
collaborative care with physicians offering education and 
tailored guidance to participants. Bogner et al. [28] looked at 
addressing patient-subjective factors that could affect 
adherence and ensured they addressed them during the 
intervention.  
Piette et al. [31] found that telephone-delivered CBT was 
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more likely to increase depression remission at 58% 
compared to 39% in usual care.  
The risk of bias summary table (Figure 4), shows 4 studies 
having a relatively high risk of bias [26, 31, 35, 36]. This is 
mirrored in discrepancies in the results, for example, Piette et 
al. [31] and Williams et al. [35] were the only 2 studies to 
have no improvement or worsening of glycaemic control, and 
both had SMD of <0.01. Interestingly, the study with the 
highest risks of bias, Weinger et al. [33] was the only study 
not to show improvements in depression outcomes.  
Huang et al. [26] projected that motivation enhancement 
therapy combined with CBT would improve HbA1c and 
depressive symptoms in patients from baseline to follow-up. 
The interventions included enhancing patients’ motivation to 
improve their self-care and introduced stress-coping 
strategies to help patients cope with hyperglycemia and other 
symptoms of their conditions. This study found that these 
interventions significantly helped to improve diabetes and 
depression control.  
Lauffenburger et al. [27] looked at delivering intensive 
insulin adherence interventions in patients with type 2 
diabetes which included regular phone consultations and a 
weekly text message program that focused on reminding 
patients on taking their medication and essentially improve 
medication adherence. They found that high-intensity 
intervention improved glycaemic control compared to low 
intensity.  
Limitations  
This analysis had limitations. Firstly, using combined results 
from different RCTs, showed differences in measured 
outcomes, specifically for the depression outcome as 
different psychometric measures were used to measure 
depression in participants. This could have been the main 
cause of the high heterogeneity. 
Another limitation is the use of different interventions in each 
of the studies. Some studies looked at collaborative care 
whilst others looked at psychotherapy and although this was 
an aim of this study to assess; the methods to each of these 
interventions were different e.g., some studies had nurses 
conduct counseling and educational sessions whilst others 
had doctors and pharmacists. In addition to that, the number 
of sessions differed between all the studies. This could have 
created a bias in the results.  
This study included only 10 RCTs with a total of 5759 
patients with all except for Lauffenburger et al. [27] having 
small sample sizes and mainly being conducted in the USA 
which means that results are not representative of the 
population as a whole, limiting generalisability. Many studies 
found for this analysis were not accessible without payment, 
for which no funding was available.  
Four of the studies included results for both Type 1 and type 
2 diabetes which could have taken the focus out away from 
the type 2 diabetes sub-group. Also, some of the studies used 
self-reporting as a form of measuring depression symptoms 
and HbA1c % which is demonstrated in the table of bias as a 
category (Figures 2 and 3) which could have introduced 
detection bias. 
Finally, sub-group analysis was not conducted for short-term 
effects compared to long-term; only long-term effects were 
analyzed. This may have identified differences in how 
interventions work by time and their estimated time of 
response. 
CONCLUSION  
In this study, the aim was to investigate whether intervention 
strategies in the form of psychological (CBT) and educational 
programs had an impact on the clinical outcomes of 
depression and diabetes compared to usual care concerning 
adherence determined by improvements in both outcomes. 
The consensus for diabetes outcome showed 6 out of 10 
studies that had an improvement in HbA1c values in the 
intervention group compared to usual care. Four of the studies 
showed either no improvement with values being 
indistinguishable or an increase in HbA1c value in the 
intervention group. Depression outcomes showed 8 out of the 
9 studies showing a significant improvement in depression 
outcomes in the intervention group compared to the usual 
group with only 1 study showing no improvement. 
These findings indicate that intervention with psychological 
and educational measures has a positive impact on depression 
outcome and is therefore reflected in the improved diabetic 
HbA1c control which shows a link between the two and 
adherence measured in diabetic control highlights an 
improvement. 
Recommendations from this study include the investigation 
of cost-effectiveness to examine the costs and clinical 
outcomes of depression and diabetes by comparing the 
intervention to usual care and estimating the cost.  Also, 
consistent CBT or educational measures need to be 
investigated over a longer period to investigate the long-term 
effects compared to the short-term effects this intervention 
will have. In addition to this, it is recommended that the 
implementation of depression screening in all diabetic 
patients be carried out regularly, to manage early depressive 
symptoms if any, and try preventative measures before 
resulting in treatment which can be difficult and result in 
adherence issues from patients. 
In conclusion, adherence follows a complex process and is 
not a singular occurrence, therefore adherence support should 
be integrated into all health consultations in diabetic patients 
with or without comorbid depression.  
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